Executives On The Move
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Executives On The Move: Changes At The Top At Aileron, KalVista And More
Recent moves in the industry include new chief medical officers at Rigel Pharmaceuticals and FibroGen, while Aileron Therapeutics and KalVista get new CEOs.
Executives On The Move: New CEOs At Nicox, Maxion Therapeutics And Fore Biotherapeutics
Other recent moves in the industry include 10 new chief financial officers, while Mithra Pharmaceuticals gets two co-chief executives officers.
Executives On The Move: Joseph Papa Joins Emergent BioSolutions As CEO Among Other Industry Moves
Recent moves within the industry include changes at the top for Ocular Therapeutix and Rayzebio, plus a new CEO for Bellicum Pharmaceuticals.
Executives On The Move: Changes At The Top At Ocuphire Pharma, YS Biopharma And More
Recent executive moves in the industry include new CEOs at Latigo Biotherapeutics and YS Biopharma Co, plus new directors at Cingulate.
AbbVie Stays On Script With Michael As Next CEO
As previously indicated, AbbVie will go with an internal candidate, president and COO Robert Michael, to succeed Richard Gonzalez as CEO. The company has recently positioned Michael prominently.
Executives On The Move: Grifols, TYK Medicines And Terns Pharmaceuticals Announce Changes
Recent C-suite moves in the industry include a new CEO for Grifols and changes at the top at Aligos Therapeutics and Cytophage Technologies.
Exscientia Focus Firmly On Pipeline After CEO Exit Scandal
The sacking of CEO Andrew Hopkins over inappropriate relationships with two employees has cast a cloud over the high-profile AI biotech.
Executives On The Move: 18 New CFOs As Five Companies Welcome New CEOs
Recent moves in the industry include new chief financial officers at 17 firms, while there are C-suite moves at Madrigal Pharmaceuticals, ACADIA Pharmaceuticals and BMS buy, Mirati Therapeutics.
Executives On The Move: New Directors At BeiGene, Mirati Therapeutics And Elevation Oncology
Recent industry appointments include new directors at Orchard Therapeutics, BeiGene and Mirati Therapeutics, among others.
Amgen Doubles Down On AI, Genomic Investments In R&D
David Reese, chief technology officer and former EVP of R&D, and newly appointed EVP of R&D Jay Bradner spoke with Scrip about how Amgen is pairing artificial intelligence with genomics plus data milestones in 2024.
Share Dealings Of Ex-CEO Cast A Cloud Over Evotec
The German biotech has distanced itself from recently resigned head Werner Lanthaler who appears to have violated the rules regarding the buying and selling of stock.
Executives On The Move: Seven New CEOs Plus Six Firms Get New CFOs
Recent executive moves in the industry include changes at the top at Karuna Therapeutics, TransCode Therapeutics and Mirum Pharmaceuticals.
Executives On The Move: The New Year Brings More Than 80 Changes At The Top
Recent executive moves in the industry include changes at the top at POINT Biopharma, Akebia Therapeutics and Acrivon Therapeutics, while 13 firms have new CEOs.
End Of An Era At Evotec as CEO Lanthaler Resigns
Evotec's highly regarded but exhausted CEO Werner Lanthaler has surprised the markets by stepping down from the post and announcing plans for an educational sabbatical "before starting my next entrepreneurial chapter."
Executives On The Move: New CEOs For 10 Companies While 8 Get New CFOs
Recent executive moves in the industry include changes at the top for Catalyst Pharmaceuticals, Edenbridge Pharmaceuticals and Eterna Therapeutics, among others.
Executives On The Move: Latest C-Suite Changes In The Industry
Valneva, Gensight Biologics and Harpoon Therapeutics are among the companies reporting executives moves in the industry recently.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.